Immunocompromised host vaccination US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Immunocompromised host vaccination. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Immunocompromised host vaccination US Medical PG Question 1: A 26-year-old man comes to the physician for a follow-up examination. He was diagnosed with HIV infection 2 weeks ago. His CD4+ T-lymphocyte count is 162/mm3 (N ≥ 500). An interferon-gamma release assay is negative. Prophylactic treatment against which of the following pathogens is most appropriate at this time?
- A. Cytomegalovirus
- B. Toxoplasma gondii
- C. Mycobacterium tuberculosis
- D. Aspergillus fumigatus
- E. Pneumocystis jirovecii (Correct Answer)
Immunocompromised host vaccination Explanation: ***Pneumocystis jirovecii***
- This patient's **CD4+ T-lymphocyte count of 162/mm3** is below the threshold of 200/mm3, indicating a significant risk for **Pneumocystis pneumonia (PCP)**, an opportunistic infection in HIV.
- Prophylaxis with **trimethoprim-sulfamethoxazole (TMP-SMX)** is highly effective and recommended for HIV patients with CD4 counts less than 200/mm3.
*Cytomegalovirus*
- **CMV prophylaxis** is generally not recommended for all HIV patients, even with low CD4 counts, unless there is evidence of active disease or extremely low CD4 counts (e.g., <50/mm3) with high viral loads.
- While CMV can cause end-organ disease in advanced HIV, routine primary prophylaxis is not standard for this CD4 level.
*Toxoplasma gondii*
- **Toxoplasma prophylaxis** is indicated for HIV patients with **CD4 counts less than 100/mm3** who are also seropositive for *Toxoplasma gondii*.
- The patient's CD4 count is 162/mm3, and there's no mention of *Toxoplasma* serostatus, making it less appropriate than PCP prophylaxis.
*Mycobacterium tuberculosis*
- The patient's **interferon-gamma release assay (IGRA) is negative**, which suggests no **latent tuberculosis infection (LTBI)**, thus making primary prophylaxis unnecessary at this time.
- While HIV patients are at high risk for TB, prophylaxis is typically given for LTBI or as secondary prophylaxis for those who have completed treatment for active TB.
*Aspergillus fumigatus*
- **Aspergillus infections** are typically seen in patients with severe **neutropenia** or those receiving high-dose corticosteroids, not primarily in HIV patients based solely on CD4 count.
- Routine prophylaxis for Aspergillus is not recommended for HIV patients, even with low CD4 counts, unless there is a specific risk factor.
Immunocompromised host vaccination US Medical PG Question 2: For which of the following patients would you recommend prophylaxis against mycobacterium avium-intracellulare?
- A. 30-year old HIV positive male with CD4 count of 20 cells/microliter and a viral load of < 50 copies/mL (Correct Answer)
- B. 22-year old HIV positive female with CD4 count of 750 cells/microliter and a viral load of 500,000 copies/mL
- C. 45-year old HIV positive female with CD4 count of 250 cells/microliter and a viral load of 100,000 copies/mL
- D. 50-year old HIV positive female with CD4 count of 150 cells/microliter and a viral load of < 50 copies/mL
- E. 36-year old HIV positive male with CD4 count of 75 cells/microliter and an undetectable viral load
Immunocompromised host vaccination Explanation: ***30-year old HIV positive male with CD4 count of 20 cells/microliter and a viral load of < 50 copies/mL***
- Prophylaxis against **Mycobacterium avium complex (MAC)** is recommended for HIV-positive individuals with a **CD4 count below 50 cells/µL** to prevent disseminated MAC infection.
- While an undetectable viral load suggests effective antiretroviral therapy (ART) in general, the extremely low CD4 count indicates severe immunosuppression, making prophylaxis crucial.
*36-year old HIV positive male with CD4 count of 75 cells/microliter and an undetectable viral load*
- The **CD4 count of 75 cells/µL** is above the threshold of 50 cells/µL for MAC prophylaxis, even though it's still low.
- An **undetectable viral load** indicates successful ART, which generally helps improve immune function over time, albeit slowly in this CD4 range.
*22-year old HIV positive female with CD4 count of 750 cells/microliter and a viral load of 500,000 copies/mL*
- A **CD4 count of 750 cells/µL** is well above the threshold for MAC prophylaxis, indicating relatively preserved immune function.
- Although the **viral load is very high**, suggesting uncontrolled HIV replication, the immune system is currently strong enough to ward off MAC.
*45-year old HIV positive female with CD4 count of 250 cells/microliter and a viral load of 100,000 copies/mL*
- A **CD4 count of 250 cells/µL** is above the threshold for MAC prophylaxis, which is 50 cells/µL.
- While the **high viral load** implies an increased risk for opportunistic infections over time, other specific prophylaxes (e.g., PCP if <200) would be considered earlier.
*50-year old HIV positive female with CD4 count of 150 cells/microliter and a viral load of < 50 copies/mL*
- A **CD4 count of 150 cells/µL** is above the threshold for MAC prophylaxis (50 cells/µL).
- An **undetectable viral load** is a positive sign of ART efficacy, but this patient would still require prophylaxis for **Pneumocystis jirovecii pneumonia (PCP)**, as her CD4 count is below 200 cells/µL.
Immunocompromised host vaccination US Medical PG Question 3: An 11-year-old boy is brought to his pediatrician by his parents for the routine Tdap immunization booster dose that is given during adolescence. Upon reviewing the patient’s medical records, the pediatrician notes that he was immunized according to CDC recommendations, with the exception that he received a catch-up Tdap immunization at the age of 8 years. When the pediatrician asks the boy’s parents about this delay, they inform the doctor that they immigrated to this country 3 years ago from Southeast Asia, where the child had not been immunized against diphtheria, tetanus, and pertussis. Therefore, he received a catch-up series at 8 years of age, which included the first dose of the Tdap vaccine. Which of the following options should the pediatrician choose to continue the boy’s immunization schedule?
- A. A single dose of Td vaccine at 18 years of age
- B. A single dose of Td vaccine now
- C. No further vaccination needed
- D. A single dose of Tdap vaccine now
- E. A single dose of Tdap vaccine at 13 years of age (Correct Answer)
Immunocompromised host vaccination Explanation: ***A single dose of Tdap vaccine at 13 years of age***
- The CDC recommends a **minimum interval of 5 years** between Tdap doses when Tdap is given as part of a catch-up series.
- Since this patient received his first Tdap at age 8, the earliest he should receive the adolescent booster is at **age 13** (5 years later).
- This timing ensures adequate spacing while still providing the recommended adolescent booster for **pertussis, tetanus, and diphtheria** protection.
- The 5-year interval prevents excessive antigen exposure and optimizes immune response.
*A single dose of Tdap vaccine now*
- Giving Tdap now would result in only a **3-year interval** from the previous Tdap dose at age 8.
- This violates the CDC recommendation of a **minimum 5-year interval** between Tdap doses.
- Shorter intervals may increase local reactogenicity without improving protection.
*A single dose of Td vaccine now*
- While this would provide tetanus and diphtheria protection, it would **not protect against pertussis**, which is a critical component of adolescent vaccination.
- The Tdap vaccine is specifically recommended for adolescents to boost waning pertussis immunity.
- Additionally, giving it now would still be earlier than the recommended 5-year interval from the previous pertussis-containing vaccine.
*A single dose of Td vaccine at 18 years of age*
- This option would result in a **10-year gap** from the last pertussis-containing vaccine, leaving the adolescent vulnerable during high-risk years.
- The adolescent Tdap booster is specifically timed for ages 11-13 to protect during peak transmission periods in middle and high school.
- Waiting until 18 would miss the critical window for pertussis protection.
*No further vaccination needed*
- While the patient completed a catch-up series, the CDC still recommends an **adolescent Tdap booster** even for those who received Tdap in a catch-up series.
- The adolescent booster is important to maintain immunity against pertussis, which wanes significantly over time.
- The booster should be given at age 13 to maintain the 5-year minimum interval.
Immunocompromised host vaccination US Medical PG Question 4: A 7-year-old African-American boy presents to his physician with fatigue, bone and abdominal pain, and mild jaundice. The pain is dull and remitting, and the patient complains it sometimes migrates from one extremity to another. His mother reports that his jaundice and pain have occurred periodically for the past 5 years. At the time of presentation, his vital signs are as follows: the blood pressure is 80/50 mm Hg, the heart rate is 87/min, the respiratory rate is 17/min, and the temperature is 36.5°C (97.7°F). On physical examination, the patient appears to be pale with mildly icteric sclera and mucous membranes. On auscultation, there is a soft systolic ejection murmur, and palpation reveals hepatosplenomegaly. His musculoskeletal examination shows no abnormalities. Laboratory investigations show the following results:
Complete blood count
Erythrocytes
3.7 x 106/mm3
Hgb
11 g/dL
Total leukocyte count
Neutrophils
Lymphocytes
Eosinophils
Monocytes
Basophils
7,300/mm3
51%
40%
2%
7%
0
Platelet count
151,000/mm3
Chemistry
Total bilirubin
3.1 mg/dL (53 µmol/L)
Direct bilirubin
0.5 mg/dL (8.55 µmol/L)
A peripheral blood smear shows numerous sickle-shaped red blood cells. Among other questions, the patient’s mother asks you how his condition would influence his vaccination schedule. Which of the following statements is true regarding vaccination in this patient?
- A. The patient’s condition does not affect his chances to get any infection; thus, additional vaccinations are not advised.
- B. The patient should not receive meningococcal, pneumococcal, or Haemophilus influenzae vaccines, because they are likely to cause complications or elicit disease in his case.
- C. The patient should receive the pneumococcal polysaccharide vaccine as soon as possible, because he is at higher risk of getting pneumococcal infection than other children.
- D. The patient should receive serogroup B meningococcal vaccination at the age of 10 years. (Correct Answer)
- E. The patient should receive serogroup B meningococcal vaccination as soon as possible, because he is at higher risk of getting meningococcal infection than other children.
Immunocompromised host vaccination Explanation: ***The patient should receive serogroup B meningococcal vaccination at the age of 10 years.***
- Patients with **sickle cell disease** (SCD) have **functional asplenia**, increasing their risk for invasive meningococcal disease from encapsulated bacteria.
- The **MenACWY vaccine** should be given starting at age 2 months for high-risk children with asplenia, with boosters every 5 years.
- The **MenB vaccine series** is recommended specifically for individuals **10 years and older** with anatomic or functional asplenia, including SCD patients.
- This statement correctly identifies the age-appropriate timing for MenB vaccination according to **ACIP guidelines**.
*The patient should receive serogroup B meningococcal vaccination as soon as possible, because he is at higher risk of getting meningococcal infection than other children.*
- While SCD patients are at increased risk for meningococcal infections, the **MenB vaccine is not recommended before age 10 years**, even in high-risk patients.
- At age 7, this patient should receive **MenACWY** if not already vaccinated, but MenB vaccination should wait until age 10.
- The timing "as soon as possible" is incorrect for MenB vaccine in this 7-year-old patient.
*The patient's condition does not affect his chances to get any infection; thus, additional vaccinations are not advised.*
- This is completely false. **Sickle cell disease causes functional asplenia**, which dramatically increases the risk of overwhelming sepsis from encapsulated organisms (*S. pneumoniae*, *N. meningitidis*, *H. influenzae* type b).
- Additional vaccinations beyond the routine schedule are **essential and life-saving** for SCD patients.
*The patient should not receive meningococcal, pneumococcal, or Haemophilus influenzae vaccines, because they are likely to cause complications or elicit disease in his case.*
- This is dangerously incorrect. These vaccines are **specifically recommended and safe** for patients with SCD.
- Patients with functional asplenia are at **highest risk** for invasive disease from these encapsulated bacteria, making vaccination crucial.
- These vaccines do not cause complications or elicit disease in SCD patients; they are inactivated or subunit vaccines.
*The patient should receive the pneumococcal polysaccharide vaccine as soon as possible, because he is at higher risk of getting pneumococcal infection than other children.*
- While SCD patients are at high risk for pneumococcal infection, the vaccination schedule is specific: **PCV13** in infancy, followed by **PPSV23** at age 2 years and older.
- At age 7, if not previously vaccinated, catch-up vaccination is needed, but "as soon as possible" without specifying the proper sequence (PCV13 first, then PPSV23) and "polysaccharide vaccine" alone is imprecise.
- The correct answer focuses on MenB at age 10, which is the most specific guideline-based recommendation among the options.
Immunocompromised host vaccination US Medical PG Question 5: A young man about to leave for his freshman year of college visits his physician in order to ensure that his immunizations are up-to-date. Because he is living in a college dormitory, his physician gives him a vaccine that prevents meningococcal disease. What type of vaccine did this patient likely receive?
- A. Live, attenuated
- B. Killed, attenuated
- C. Toxoid
- D. Conjugated polysaccharide (Correct Answer)
- E. Killed, inactivated
Immunocompromised host vaccination Explanation: ***Conjugated polysaccharide***
- The **meningococcal vaccine** commonly administered to college students is a **polysaccharide vaccine** wherein the polysaccharide antigens are conjugated to a protein carrier.
- This **conjugation** improves the immune response by converting a T-independent antigen into a T-dependent one, inducing better memory responses and allowing for vaccination of infants.
*Live, attenuated*
- Live, attenuated vaccines contain a **weakened form of the pathogen** that can replicate but does not cause disease, such as the MMR or varicella vaccine.
- While they elicit strong, long-lasting immunity, the meningococcal vaccine is not typically of this type due to the risk of opportunistic infection, especially in immunocompromised individuals.
*Killed, attenuated*
- This term is a **contradiction**; vaccines are either **killed (inactivated)** or **live (attenuated)**, but not both.
- Attenuation implies weakening, for which the organism would still be alive.
*Toxoid*
- **Toxoid vaccines** are made from inactivated bacterial toxins, used to protect against diseases where the toxin, not the bacterium itself, causes the disease, such as diphtheria and tetanus.
- Meningococcal disease is primarily caused by **direct bacterial invasion and inflammation**, not solely by a toxin.
*Killed, inactivated*
- **Killed, inactivated vaccines** contain whole pathogens that have been killed and cannot replicate, such as the inactivated poliovirus vaccine.
- While there are inactivated meningococcal vaccines, the most common type for broad use, especially in college settings, is the conjugated polysaccharide vaccine, which elicits a stronger and more long-lasting immune response against multiple serotypes compared to plain inactivated whole-cell vaccines.
Immunocompromised host vaccination US Medical PG Question 6: An epidemiologist is evaluating the efficacy of Noxbinle in preventing HCC deaths at the population level. A clinical trial shows that over 5 years, the mortality rate from HCC was 25% in the control group and 15% in patients treated with Noxbinle 100 mg daily. Based on this data, how many patients need to be treated with Noxbinle 100 mg to prevent, on average, one death from HCC?
- A. 20
- B. 73
- C. 10 (Correct Answer)
- D. 50
- E. 100
Immunocompromised host vaccination Explanation: ***10***
- The **number needed to treat (NNT)** is calculated by first finding the **absolute risk reduction (ARR)**.
- **ARR** = Risk in control group - Risk in treatment group = 25% - 15% = **10%** (or 0.10).
- **NNT = 1 / ARR** = 1 / 0.10 = **10 patients**.
- This means that **10 patients must be treated with Noxbinle to prevent one death from HCC** over 5 years.
*20*
- This would result from an ARR of 5% (1/0.05 = 20), which is not supported by the data.
- May arise from miscalculating the risk difference or incorrectly halving the actual ARR.
*73*
- This value does not correspond to any standard calculation of NNT from the given mortality rates.
- May result from confusion with other epidemiological measures or calculation error.
*50*
- This would correspond to an ARR of 2% (1/0.02 = 50), which significantly underestimates the actual risk reduction.
- Could result from incorrectly calculating the difference as a proportion rather than absolute percentage points.
*100*
- This would correspond to an ARR of 1% (1/0.01 = 100), grossly underestimating the treatment benefit.
- May result from confusing ARR with relative risk reduction or other calculation errors.
Immunocompromised host vaccination US Medical PG Question 7: A 27-year-old man presents to the family medicine clinic for a routine check-up. The patient recently accepted a new job at a childcare center and the employer is requesting his vaccination history. After checking the records from the patient’s childhood, the physician realizes that the patient never had the varicella vaccine. The patient is unsure if he had chickenpox as a child, and there is no record of him having had the disease in the medical record. There is no significant medical history, and the patient takes no current medications. The patient’s heart rate is 82/min, respiratory rate is 14/min, temperature is 37.5°C (99.5°F), and blood pressure is 120/72 mm Hg. The patient appears alert and oriented. Auscultation of the heart reveals no murmurs, rubs, or gallops. The lungs are clear to auscultation bilaterally. With regard to the varicella vaccine, which of the following is recommended for the patient at this time?
- A. Two doses of vaccine (Correct Answer)
- B. One dose of the vaccine
- C. Wait until patient turns 50
- D. Serology then administer the vaccine (2 doses)
- E. Serology then administer the vaccine (1 dose)
Immunocompromised host vaccination Explanation: ***Two doses of vaccine***
- According to **CDC/ACIP guidelines**, adults without evidence of immunity to varicella should receive **two doses of varicella vaccine** (4-8 weeks apart) without prior serologic testing.
- The patient has no documentation of vaccination or prior disease, and works in a **high-risk setting (childcare center)** with frequent exposure to children.
- **Routine serologic testing is NOT recommended** before vaccination as it delays protection, is cost-ineffective, and the vaccine is safe even if the person is already immune.
- Two doses provide **97% protection** against varicella and significant protection against breakthrough disease.
*Serology then administer the vaccine (2 doses)*
- While the two-dose schedule is correct, obtaining serology first is **not recommended by CDC** for routine adult varicella vaccination.
- Serologic testing delays protection and is cost-ineffective; the vaccine is safe to give even if immunity already exists.
- Serology may be considered in special circumstances (e.g., for healthcare workers when cost-benefit analysis favors testing), but not routinely.
*One dose of the vaccine*
- A single dose provides only **80-85% protection** and is insufficient for adults.
- **Two doses are required** for optimal immunity in adults without evidence of immunity.
*Wait until patient turns 50*
- This confuses the **varicella (chickenpox) vaccine** with the **herpes zoster (shingles) vaccine** (Shingrix), which is recommended at age 50.
- The patient needs immediate protection due to high-risk occupational exposure and current susceptibility.
*Serology then administer the vaccine (1 dose)*
- This option is incorrect for two reasons: serology is not routinely recommended, and one dose is insufficient for adult vaccination.
- Adults require a **two-dose series** for adequate protection against varicella.
Immunocompromised host vaccination US Medical PG Question 8: A 19-year-old male arrives to student health for an annual check up. He is up to date on his infant and childhood vaccinations up to age 10. At age 12, he received a single dose of the tetanus, diphtheria, and acellular pertussis vaccine, and a quadrivalent meningococcal conjugate vaccine. A month ago, he received the influenza vaccine. The patient has no significant medical history. He takes over the counter ibuprofen for occasional headaches. He has a father with hypertension and hyperlipidemia, and his brother has asthma. He is sexually active with his current girlfriend. He denies tobacco use, illicit drug use, and recent or future travel. The patient’s temperature is 98°F (36.7°C), blood pressure is 118/78 mmHg, pulse is 70/min, and respirations are 14/min with an oxygen saturation of 99% O2 on room air. A physical examination is normal. What of the following is the best recommendation for vaccination?
- A. Human papillomavirus vaccine (Correct Answer)
- B. Hepatitis A vaccine
- C. Herpes zoster vaccine
- D. Pneumococcal vaccine
- E. Tetanus and reduced diphtheria toxoid booster
Immunocompromised host vaccination Explanation: ***Human papilloma virus***
- This patient, being 19 years old and **sexually active**, is a prime candidate for the **HPV vaccine** to prevent infections that can lead to various cancers.
- The CDC recommends routine HPV vaccination at age 11-12, but catch-up vaccination is recommended for individuals up to age 26 if not adequately vaccinated previously.
*Hepatitis A vaccine*
- The Hepatitis A vaccine is generally recommended for individuals at **increased risk** of infection, such as travelers to endemic areas, men who have sex with men, or those with chronic liver disease, none of which apply to this patient.
- There is no indication for routine vaccination without specific risk factors in this otherwise healthy young male.
*Herpes zoster vaccine*
- The herpes zoster (shingles) vaccine is recommended for adults **age 50 years and older** to prevent shingles.
- This patient is only 19 years old, making him too young for this vaccine recommendation.
*Pneumococcal vaccine*
- Pneumococcal vaccines (PCV13 and PPSV23) are typically recommended for **young children**, adults **65 years and older**, or individuals with **certain underlying medical conditions** (e.g., chronic heart, lung, or kidney disease, or immunocompromised states).
- This 19-year-old patient has no such risk factors for pneumococcal disease.
*Tetanus and reduced diphtheria toxoid booster*
- The patient received a Tdap vaccine at age 12. A Td booster is recommended **every 10 years** for adults.
- Since it has been only 7 years since his last Tdap vaccine, he is not due for a Td booster at this time.
Immunocompromised host vaccination US Medical PG Question 9: A 34-year-old man comes to the physician for a routine health maintenance examination. He was diagnosed with HIV 8 years ago. He is currently receiving triple antiretroviral therapy. He is sexually active and uses condoms consistently. He is planning a trip to Thailand with his partner to celebrate his 35th birthday in 6 weeks. His last tetanus and diphtheria booster was given 4 years ago. He received three vaccinations against hepatitis B 5 years ago. He had chickenpox as a child. Other immunization records are unknown. Vital signs are within normal limits. Cardiopulmonary examination shows no abnormalities. Leukocyte count shows 8,700/mm3, and CD4+ T-lymphocyte count is 480 cells/mm3 (Normal ≥ 500); anti-HBs is 150 mIU/mL. Which of the following recommendations is most appropriate at this time?
- A. Yellow fever vaccine
- B. Hepatitis B vaccine
- C. Tetanus, diphtheria, pertussis vaccine (Tdap)
- D. Measles, mumps, rubella vaccine
- E. No vaccination (Correct Answer)
Immunocompromised host vaccination Explanation: ***Correct: No vaccination***
- Given the patient's current immunization status and clinical scenario, **none of the listed vaccines are indicated at this time**.
- His CD4+ count of 480 cells/mm³ indicates relatively preserved immune function on effective antiretroviral therapy.
- His **anti-HBs level of 150 mIU/mL** demonstrates **adequate hepatitis B immunity** (protective level ≥10 mIU/mL).
- His **tetanus-diphtheria booster was given 4 years ago**, and routine boosters are recommended every **10 years**, so he is not due for another 6 years.
*Incorrect: Yellow fever vaccine*
- **Thailand is not a yellow fever endemic country**, so yellow fever vaccination is **not required or recommended** for travel there.
- Yellow fever vaccine is a **live attenuated vaccine** that can be given to HIV-positive patients with **CD4+ counts ≥200 cells/mm³** when travel to endemic areas (parts of Africa and South America) is necessary.
- Since the patient has a CD4+ count of 480 and Thailand doesn't require this vaccine, this is not applicable.
*Incorrect: Hepatitis B vaccine*
- The patient's **anti-HBs level of 150 mIU/mL** indicates **adequate protective immunity** against hepatitis B.
- A level ≥10 mIU/mL is considered protective, so **no booster is needed**.
*Incorrect: Tetanus, diphtheria, pertussis vaccine (Tdap)*
- **Tetanus-diphtheria boosters are recommended every 10 years**.
- The patient received his last booster **4 years ago**, so he is **not due** for another booster at this time.
- There is no specific indication for **pertussis vaccination** (e.g., pregnancy, close contact with infants).
*Incorrect: Measles, mumps, rubella vaccine*
- **MMR is a live attenuated vaccine** that is **contraindicated** in HIV-positive individuals with **CD4+ counts <200 cells/mm³**.
- While this patient's CD4+ count is 480, MMR should only be given to HIV patients if they lack immunity and have CD4 ≥200.
- There is **no documented need** for MMR based on the clinical scenario provided, and his immunity status to these infections is unknown.
- Without evidence of susceptibility or specific exposure risk, vaccination is not indicated.
Immunocompromised host vaccination US Medical PG Question 10: A 12-month-old boy presents for a routine checkup. The patient immigrated from the Philippines with his parents a few months ago. No prior immunization records are available. The patient’s mother claims that he had a series of shots at 6 months of age which gave him a severe allergic reaction with swelling of the tongue and the face. She also remembers that he had the same reaction when she introduced solid foods to his diet, including carrots, eggs, and bananas. Which of the following vaccinations are not recommended for this patient?
- A. Measles, mumps, and rubella (MMR) vaccine
- B. Hepatitis B vaccine
- C. Varicella vaccine
- D. Intranasal influenza vaccine
- E. Intramuscular influenza vaccine (Correct Answer)
Immunocompromised host vaccination Explanation: ***Important Note on Current Guidelines***
Based on **current CDC/ACIP guidelines (2023-2024)**, egg allergy alone is **no longer a contraindication** to influenza vaccines. However, this question tests knowledge of vaccine safety in the context of **severe anaphylaxis to a prior vaccination**.
***Intramuscular influenza vaccine***
- **Historically**, this was considered the most concerning option for patients with severe egg allergy, as many influenza vaccines were produced using egg-based culture methods
- **Current practice**: Per CDC guidelines, persons with egg allergy of any severity can receive any age-appropriate influenza vaccine, as egg protein content is minimal or absent in modern formulations
- However, if this patient had a **documented anaphylactic reaction to the influenza vaccine itself** (not just eggs), then it would be contraindicated
- Given the timing (6 months) and symptoms described, this represents the **historically correct answer**, though modern practice has evolved
*Measles, mumps, and rubella (MMR) vaccine*
- MMR vaccine is grown in **chick embryo fibroblast cells**, NOT in eggs, and contains **no egg protein**
- **Safe for patients with egg allergy** - no contraindication based on egg allergy
- Should be administered on schedule for catch-up immunization
*Hepatitis B vaccine*
- Produced using **recombinant DNA technology in yeast cells**
- Contains **no egg protein** and no animal-derived proteins
- **No contraindication** for this patient - safe to administer
*Varicella vaccine*
- Grown in **human diploid cell cultures**, NOT in eggs
- Contains **no egg protein**
- **Safe for patients with egg allergy** - no contraindication
- Should be administered as part of catch-up immunization
*Intranasal influenza vaccine (LAIV)*
- Like the intramuscular formulation, **current guidelines allow administration** to patients with egg allergy of any severity
- Contains similar or less egg protein than inactivated vaccines in modern formulations
- **Not contraindicated** based solely on egg allergy per current CDC guidelines
More Immunocompromised host vaccination US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
